JP2004536112A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536112A5
JP2004536112A5 JP2003510654A JP2003510654A JP2004536112A5 JP 2004536112 A5 JP2004536112 A5 JP 2004536112A5 JP 2003510654 A JP2003510654 A JP 2003510654A JP 2003510654 A JP2003510654 A JP 2003510654A JP 2004536112 A5 JP2004536112 A5 JP 2004536112A5
Authority
JP
Japan
Prior art keywords
carbonyl
dichlorophenoxy
benzenesulfonamide
bipiperidin
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003510654A
Other languages
English (en)
Japanese (ja)
Other versions
JP3857270B2 (ja
JP2004536112A (ja
Filing date
Publication date
Priority claimed from GB0116179A external-priority patent/GB0116179D0/en
Priority claimed from GB0123037A external-priority patent/GB0123037D0/en
Application filed filed Critical
Priority claimed from PCT/SE2002/001311 external-priority patent/WO2003004487A1/en
Publication of JP2004536112A publication Critical patent/JP2004536112A/ja
Publication of JP2004536112A5 publication Critical patent/JP2004536112A5/ja
Application granted granted Critical
Publication of JP3857270B2 publication Critical patent/JP3857270B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003510654A 2001-07-02 2002-07-01 ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体 Expired - Fee Related JP3857270B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0116179A GB0116179D0 (en) 2001-07-02 2001-07-02 Chemical compounds
GB0123037A GB0123037D0 (en) 2001-09-25 2001-09-25 Chemical compounds
PCT/SE2002/001311 WO2003004487A1 (en) 2001-07-02 2002-07-01 Piperidine derivatives useful as modulators of chemokine receptor activity

Publications (3)

Publication Number Publication Date
JP2004536112A JP2004536112A (ja) 2004-12-02
JP2004536112A5 true JP2004536112A5 (enExample) 2006-01-05
JP3857270B2 JP3857270B2 (ja) 2006-12-13

Family

ID=26246268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510654A Expired - Fee Related JP3857270B2 (ja) 2001-07-02 2002-07-01 ケモカイン受容体活性のモジュレーターとして有用なピペリジン誘導体

Country Status (25)

Country Link
US (1) US7307090B2 (enExample)
EP (2) EP1604982A1 (enExample)
JP (1) JP3857270B2 (enExample)
KR (1) KR20040013090A (enExample)
CN (1) CN1545509A (enExample)
AR (1) AR042401A1 (enExample)
AT (1) ATE319703T1 (enExample)
BR (1) BR0210733A (enExample)
CA (1) CA2452597A1 (enExample)
CO (1) CO5540307A2 (enExample)
CY (1) CY1106095T1 (enExample)
DE (1) DE60209736T2 (enExample)
DK (1) DK1404667T3 (enExample)
ES (1) ES2258642T3 (enExample)
HU (1) HUP0401886A2 (enExample)
IL (1) IL159256A0 (enExample)
IS (1) IS7094A (enExample)
MX (1) MXPA03011722A (enExample)
NO (1) NO20035729L (enExample)
NZ (1) NZ530202A (enExample)
PL (1) PL368041A1 (enExample)
PT (1) PT1404667E (enExample)
RU (1) RU2004100839A (enExample)
SA (1) SA02230184B1 (enExample)
WO (1) WO2003004487A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
US6949590B2 (en) * 2002-01-10 2005-09-27 University Of Washington Hydrogels formed by non-covalent linkages
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
SE0200844D0 (sv) * 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
US7030115B2 (en) * 2002-03-21 2006-04-18 Abbott Laboratories N-sulfonylurea apoptosis promoters
CA2479362C (en) * 2002-03-21 2011-01-04 Abbott Laboratories N-sulfonylurea apoptosis promoters
AR039156A1 (es) 2002-03-28 2005-02-09 Novartis Ag Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US20040192738A1 (en) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it
SE0300957D0 (sv) * 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0302956D0 (sv) * 2003-11-07 2003-11-07 Astrazeneca Ab Chemical compounds
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
SE0403003D0 (sv) * 2004-12-09 2004-12-09 Astrazeneca Ab Chemical compound 1
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006126948A1 (en) * 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
TW200722419A (en) * 2005-05-27 2007-06-16 Astrazeneca Ab Chemical compounds
BRPI0613563A2 (pt) 2005-07-21 2012-01-17 Astrazeneca Ab novos derivados de piperidina
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
WO2007090836A2 (en) * 2006-02-10 2007-08-16 Janssen Pharmaceutica N.V. Piperidine derivatives as cxcr3 receptor antagonists
JP2009526014A (ja) * 2006-02-10 2009-07-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Cxcr3受容体拮抗薬としてのピペリジン誘導体
CA2697551C (en) * 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
ES2489040T3 (es) 2008-12-03 2014-09-01 The Scripps Research Institute Cultivos de células madre
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
MA50665A (fr) 2017-09-25 2020-08-05 Chemocentryx Inc Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
TWI730297B (zh) * 2018-02-27 2021-06-11 日商組合化學工業股份有限公司 巰基酚化合物的製造方法及巰基酚化合物的中間體

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (enExample) 1969-03-19 1971-10-20
US4556660A (en) 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
US4634704A (en) 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4695575A (en) 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
AU2915892A (en) 1991-11-14 1993-06-15 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
GB9319534D0 (en) 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU5966096A (en) 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
NZ333513A (en) 1996-07-10 2000-04-28 Schering Corp 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
EP0821954A1 (en) 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
CZ43399A3 (cs) * 1996-08-15 1999-07-14 Schering Corporation Etheroví muskarinní antagonisté
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
EP1052992A1 (en) 1998-02-02 2000-11-22 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
TWI245763B (en) 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
US6294555B1 (en) 1998-04-28 2001-09-25 Dainippon Pharmaceutical Co., Ltd. 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
CN1146559C (zh) 1998-06-30 2004-04-21 先灵公司 毒蕈碱性拮抗剂
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003529531A (ja) 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換オキソアザへテロシクリルXa因子阻害剤
CA2347912A1 (en) 1998-12-18 2000-06-22 Soo S. Ko Heterocyclic piperidines as modulators of chemokine receptor activity
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CZ301161B6 (cs) 1999-05-04 2009-11-18 Schering Corporation Piperidinopiperidylový derivát užitecný jako CCR5 antagonista, farmaceutický prostredek jej obsahující
SE9902551D0 (sv) 1999-07-02 1999-07-02 Astra Pharma Prod Novel compounds
CA2382755A1 (en) 1999-07-28 2001-02-01 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
IT1307809B1 (it) 1999-10-21 2001-11-19 Menarini Ricerche Spa Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
CZ20032636A3 (cs) 2001-03-29 2003-12-17 Schering Corporation Látky antagonizující CCR5
GB0107907D0 (en) 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
SE0300850D0 (sv) 2003-03-25 2003-03-25 Astrazeneca Ab Chemical compounds
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
RU2006100190A (ru) 2003-06-13 2006-08-10 Шеринг Акциенгезельшафт (De) Производные хинолиламида в качестве антагонистов ccr-5

Similar Documents

Publication Publication Date Title
RU2004100839A (ru) Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов
RU2007107189A (ru) Производные арилпиридина
CN103435524B (zh) 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
ES2719101T3 (es) Derivados de hidroxilamina N-acilados y derivados de hidroxilamina o-acilados
AU2003267614B2 (en) Cyclohexyl sulphone derivatives as gamma-secretase inhibitors
JP2013525293A5 (enExample)
JP2004517080A5 (enExample)
US5760066A (en) Compounds and methods for inhibiting hyper-proliferative cell growth
JP2010540452A5 (enExample)
RU2002122100A (ru) Новые соединения
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
RU2006104697A (ru) Лекарственное средство для лечения пигментации кожи
JP2011517689A5 (enExample)
JP2016094401A (ja) ビスアシル化ヒドロキシルアミン誘導体
JP2004502670A5 (enExample)
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
EP1666469A1 (en) Plasminogen activator inhibitor-1 inhibitor
RU2457201C2 (ru) (2r)-2-[(4-сульфонил)аминофенил]пропанамиды и содержащие их фармацевтические композиции
JP2008545686A5 (enExample)
JP2008524119A5 (enExample)
RU2005131846A (ru) Сульфоновые кислоты, производные указанных кислот и содержащие их фармацевтические композиции
JP2006516626A5 (enExample)
JP2004524345A5 (enExample)
RU2009114545A (ru) Проиводные 3-амино-пиридина для лечения метаболических нарушений
JP2010504322A5 (enExample)